

**New Frontiers in
RTK Signaling & Therapeutics**
**A Joint Cancer Signaling Networks
And
Developmental Therapeutics Retreat**

Thursday, January 20, 2022
10:00 AM – 3:10 PM

10:00 am - 10:05 am	Welcome
Session 1: FGFR and ALK – Moderator: Karen Anderson, PhD	
10:05 am – 10:30 am	Patient-derived Tumor Models to Discover New Combination Therapies For FGFR Fusion Positive Cancers Karen Anderson, PhD
10:30 am – 10:55 am	ImmunoPET Imaging of Receptor Tyrosine Kinases Bernadette Marquez Nostra, PhD
10:55 am – 11:20am	Structure of a Neuroblastoma Kinase: How to Prevent ALK From Taking a “Selfie” Daryl Klein, MD, PhD
11:20 am – 11:30 am	Break
Keynote Speaker – Introduction by Barbara Burtness, MD	
11:30 am – 12:30 pm	Multimodal Precision Immunotherapy: Co-Targeting the HER3-mTOR Oncogenic Signaling Network and PD-1 J. Silvio Gutkind, PhD, Distinguished Professor and Chair
12:30 pm - 1:00 pm	Lunch Break
Session 2: ERBB Family (I) – Moderator: David Stern, PhD	
1:00 pm – 1:25 pm	ErbB2 and Breast Cancer: What’s Calcium Got to Do With It? John Wysolmerski, MD
1:25 pm – 1:50 pm	The Biology of EGFR-Driven Lung Cancer Katerina Politi, PhD
1:50 pm – 1:55 pm	Break
Session 3: ERBB Family (II) – Moderator: Katerina Politi - PhD	
1:55 pm – 2:20 pm	EGFR Mutations in Glioblastoma Alter Ligand Bias Mark Lemmon, PhD, FRS
2:20 pm – 2:45 pm	Evolution of HER2-targeted Antibody Drug Conjugates in Breast Cancer Ian Krop, MD, PhD
2:45 pm – 3:10 pm	ERBB2 Low: New Drugs Need New Assays David Rimm, MD, PhD